FULC

7.65

0.26% 0.02

Dopo l'orario di chiusura: 7.65

Fulcrum Therapeutics Inc (FULC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$7.63

Aprire:

$7.63

Volume 24 ore:

536.83K

Relative Volume:

0.38

Capitalizzazione di mercato:

$509.49M

Reddito:

$2.81M

Utile/perdita netta:

$-97.34M

Rapporto P/E:

-4.8418

EPS:

-1.58

Flusso di cassa netto:

$-91.47M

1 W Prestazione:

-6.36%

1M Prestazione:

-28.03%

6M Prestazione:

+9.29%

1 anno Prestazione:

+163.79%

Intervallo 1D:

$7.34

$7.83

Intervallo di 1 settimana:

$7.34

$8.30

Portata 52W:

$2.315

$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Nome

Fulcrum Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

617-651-8851

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

Cinguettio

@fulcrumtx

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FULC Fulcrum Therapeutics Inc	7.65	509.49M	2.81M	-97.34M	-91.47M	-1.58
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-12	Iniziato	JP Morgan	Overweight
2025-11-24	Iniziato	Truist	Buy
2025-07-29	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-05-23	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-05-15	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-09-13	Downgrade	H.C. Wainwright	Buy → Neutral
2024-09-12	Downgrade	BofA Securities	Neutral → Underperform
2024-09-12	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2024-09-12	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-12	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2024-09-12	Downgrade	Stifel	Buy → Hold
2024-09-09	Aggiornamento	BofA Securities	Underperform → Neutral
2024-05-20	Iniziato	Cantor Fitzgerald	Overweight
2024-03-13	Iniziato	RBC Capital Mkts	Outperform
2023-09-25	Iniziato	Goldman	Neutral
2023-08-23	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-08-22	Aggiornamento	Stifel	Hold → Buy
2023-05-04	Downgrade	Goldman	Buy → Neutral
2023-03-10	Downgrade	Credit Suisse	Outperform → Neutral
2023-03-10	Downgrade	H.C. Wainwright	Buy → Neutral
2023-03-09	Downgrade	Stifel	Buy → Hold
2023-02-28	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2023-02-24	Downgrade	BofA Securities	Neutral → Underperform
2022-11-15	Iniziato	Goldman	Buy
2022-03-08	Iniziato	Oppenheimer	Outperform
2022-03-03	Aggiornamento	BofA Securities	Underperform → Neutral
2021-08-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-22	Iniziato	Credit Suisse	Outperform
2021-03-02	Iniziato	Stifel	Buy
2020-10-16	Iniziato	Piper Sandler	Overweight
2020-08-12	Downgrade	BofA Securities	Neutral → Underperform
2020-08-12	Reiterato	H.C. Wainwright	Buy
2020-08-12	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-06-19	Downgrade	BofA/Merrill	Buy → Neutral
2020-06-17	Iniziato	BTIG Research	Buy
2019-10-03	Iniziato	H.C. Wainwright	Buy
2019-08-12	Iniziato	BofA/Merrill	Buy

Mostra tutto

Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie

02:25 AM

Whats next for Fulcrum Therapeutics Inc stock2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn

02:25 AM

Mar 12, 2026

Aug Macro: What’s next for Fulcrum Therapeutics Inc. stock2026 EndofYear Setup & Free Verified High Yield Trade Plans - baoquankhu1.vn

Mar 12, 2026

Mar 10, 2026

Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell By Investing.com - Investing.com Canada

Mar 10, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Mar 10, 2026

Fulcrum Therapeutics (FULC) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 10, 2026

Mar 09, 2026

Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says - Investing.com Canada

Mar 09, 2026

Mar 07, 2026

Why Fulcrum Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Highlights & Daily Price Action Insights - Naître et grandir

Mar 07, 2026

Bullish analyst sentiment on Fulcrum Therapeutics (FULC) following positive updates from Phase 1b PIONEER study - MSN

Mar 07, 2026

Mar 06, 2026

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 06, 2026

Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Mar 06, 2026

Bull Run: Can Fulcrum Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn

Mar 06, 2026

Mar 04, 2026

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - 富途牛牛

Mar 04, 2026

Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn

Mar 04, 2026

Mar 03, 2026

Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn

Feb 27, 2026

What is HC Wainwright’s Forecast for FULC Q1 Earnings? - Defense World

Feb 27, 2026

Feb 26, 2026

Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha

Feb 26, 2026